TY - JOUR
T1 - Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
AU - Okikiolu, Jumoke
AU - Woodley, Claire
AU - Cadman-Davies, Llywelyn
AU - O'Sullivan, Jennifer
AU - Radia, Deepti
AU - Garcia, Natalia Curto
AU - Harrington, Patrick
AU - Kordasti, Shahram
AU - Asirvatham, Susan
AU - Sriskandarajah, Priya
AU - Saunders, Jamie
AU - Saha, Chandan
AU - Sanchez, Irene
AU - deLavallade, Hugues
AU - McLornan, Donal P.
AU - Harrison, Claire N.
N1 - Funding Information:
Patrick Harrington: research funding from Bristol Myers Squibb, Honoraria and Incyte. Claire N. Harrison: Advisory board and speaker fees: AOP and Roche.
Publisher Copyright:
© 2022
PY - 2023/1
Y1 - 2023/1
N2 - Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.
AB - Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.
KW - Essential Thrombocythaemia
KW - IFN
KW - MPN
KW - Polycythaemia Vera
UR - http://www.scopus.com/inward/record.url?scp=85144901182&partnerID=8YFLogxK
U2 - 10.1016/j.lrr.2022.100360
DO - 10.1016/j.lrr.2022.100360
M3 - Article
AN - SCOPUS:85144901182
SN - 2213-0489
VL - 19
JO - Leukemia Research Reports
JF - Leukemia Research Reports
M1 - 100360
ER -